Lazard Asset Management LLC Affimed N.V. Transaction History

Lazard Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $51 - $98	91 Added 0.64%	14,274 $8,000
Q1 2023 May 15, 2023	BUY	$0.66 - $1.29 $1,906 - $3,725	2,888 Added 25.57%	14,183 $10,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $14,139 - $31,492	-12,854 Reduced 53.23%	11,295 $14,000
Q2 2022 Aug 09, 2022	BUY	$2.27 - $4.86 $54,818 - $117,364	24,149 New	24,149 $66,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $72,513 - $98,298	-13,089 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$3.16 - $7.03 $41,361 - $92,015	13,089 New	13,089 $76,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.